Kenneth Plunkitt.

Tomassoni, M.D., Paul A. Friedman, M.D., N.A. Tag Estes, III, M.D., John Ip, M.D., Imran Niazi, M.D., Kenneth Plunkitt, M.D., Rajesh Banker, M.D., James Porterfield, M.D., James E. Ip, M.D., and Srinivas R. Dukkipati, M.D. For the LEADLESS II Research Investigators: Percutaneous Implantation of an Entirely Intracardiac Leadless Pacemaker.. Vivek Y. Reddy, M.D., Derek V. Exner, M.D., M.P.H., Daniel J. Cantillon, M.D., Rahul Doshi, M.D., T. Jared Bunch, M.D., Gery F., a late-stage drug development company specific in endocrine and oncology therapy, today reported benefits on the scientific activity of perifosine , the Company’s novel, first-in-class potentially, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine ) as cure for advanced, metastatic colorectal cancers. Abstract #3531, entitled, ‘Final results of a randomized Stage 2 study of perifosine in conjunction with capecitabine versus capecitabine plus placebo in sufferers with second – or third-line metastatic colorectal tumor ‘ is being provided today in a poster conversation held through the 2010 Annual Interacting with of the American Society of Clinical Oncology held in Chicago.